Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China

被引：0
|
作者：
Lifeng Mu
Benhong Zhou
机构：
[1] Renmin Hospital of Wuhan University,Department of Pharmacy
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Alectinib; China; Cost-effectiveness; Non-small-cell lung cancer; Oncology; Survival extrapolation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：968 / 970
页数：2
相关论文
共 50 条
  • [1] Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
    Mu, Lifeng
    Zhou, Benhong
    ADVANCES IN THERAPY, 2020, 37 (02) : 968 - 970
  • [2] Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China”
    Haijing Guan
    Yanan Sheng
    Wanjie Guo
    Sheng Han
    Luwen Shi
    Advances in Therapy, 2020, 37 : 971 - 972
  • [3] Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China"
    Guan, Haijing
    Sheng, Yanan
    Guo, Wanjie
    Han, Sheng
    Shi, Luwen
    ADVANCES IN THERAPY, 2020, 37 (02) : 971 - 972
  • [4] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Haijing Guan
    Yanan Sheng
    Wanjie Guo
    Sheng Han
    Luwen Shi
    Advances in Therapy, 2019, 36 : 1114 - 1125
  • [5] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Guan, Haijing
    Sheng, Yanan
    Guo, Wanjie
    Han, Sheng
    Shi, Luwen
    ADVANCES IN THERAPY, 2019, 36 (05) : 1114 - 1125
  • [6] Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
    Peters, Solange
    Camidge, D. Ross
    Shaw, Alice T.
    Gadgeel, Shirish
    Ahn, Jin S.
    Kim, Dong-Wan
    Ou, Sai-Hong I.
    Perol, Maurice
    Dziadziuszko, Rafal
    Rosell, Rafael
    Zeaiter, Ali
    Mitry, Emmanuel
    Golding, Sophie
    Balas, Bogdana
    Noe, Johannes
    Morcos, Peter N.
    Mok, Tony
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 829 - 838
  • [7] Alectinib for ALK-positive non-small-cell lung cancer
    Rossi, Antonio
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (08) : 1005 - 1013
  • [8] Alectinib in resected ALK-positive non-small-cell lung cancer
    Gourmet, Anais
    Ferrari, Victoria
    BULLETIN DU CANCER, 2024, 111 (10) : 905 - 906
  • [9] Alectinib for treatment of ALK-positive non-small-cell lung cancer
    Avrillon, Virginie
    Perol, Maurice
    FUTURE ONCOLOGY, 2017, 13 (04) : 321 - 335
  • [10] Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Dziadziuszko, Rafal
    Ahn, Jin Seok
    Barlesi, Fabrice
    Nishio, Makoto
    Lee, Dae Ho
    Lee, Jong-Seok
    Zhong, Wenzhao
    Horinouchi, Hidehito
    Mao, Weimin
    Hochmair, Maximilian
    de Marinis, Filippo
    Migliorino, M. Rita
    Bondarenko, Igor
    Lu, Shun
    Wang, Qun
    Ochi Lohmann, Tania
    Xu, Tingting
    Cardona, Andres
    Ruf, Thorsten
    Noe, Johannes
    Solomon, Benjamin J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14): : 1265 - 1276
12345